贝达药业：本次发行所募集资金在扣除发行费用后全部用于公司

Group 1 - The core viewpoint of the article is that Beida Pharmaceutical plans to utilize the funds raised from its issuance for various purposes, including research and development, potential acquisitions, and expanding its marketing network and operational capabilities [2]. Group 2 - The funds raised will be allocated after deducting issuance costs and may support ongoing research pipelines [2]. - The company aims to explore potential acquisitions to enhance its pipeline [2]. - Additional uses of the funds include expanding its innovative ecosystem, marketing network, and market development in key therapeutic areas, as well as general corporate purposes [2].